SPECT quantitation of iodine-131 concentration in phantoms and human tumors

O. Israel, G. Iosilevsky, D. Front, L. Bettman, A. Frenkel, S. Ish-Shalom, M. Steiner, M. Ben-Harush, G. M. Kolodny

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


The validity of SPECT measurement of iodine-131 (131I) concentration was tested in vitro in phantoms and in vivo by measuring bladder urine concentrations. Phantom studies comparing known and SPECT measured concentrations showed a good correlation for 131I (r = 0.98, s.e.e. = 20.94 counts/voxel) for phantoms of 25 to 127 cc and concentrations of 0.13 to 9.5 μCi/cc. The in vivo, in vitro correlation of 131I concentrations in the urine was also good (r = 0.98, s.e.e. = 0.677 μCi/cc). Quantitative SPECT was used to calculate the effective half-life and dosimetry of radioiodine in 12 sites of thyroid carcinoma in seven patients. SPECT was also used to determine the dosimetry of [131I]MIBG (metaiodobenzylguanidine) in two patients with carcinoid, two with neuroblastoma, and one with pheochromocytoma. The radiation dose for thyroid carcinoma metastases varied between 6.3 and 276.9 rad/mCi. The dose from MIBG varied between 13.4 and 57.8 rad/mCi. These results indicate the validity of quantitative SPECT for in vivo measurement of 131I and the need to measure the concentration of 131I in individual human tumor sites.

Original languageEnglish
Pages (from-to)1945-1949
Number of pages5
JournalJournal of Nuclear Medicine
Issue number12
StatePublished - 1 Dec 1990
Externally publishedYes

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'SPECT quantitation of iodine-131 concentration in phantoms and human tumors'. Together they form a unique fingerprint.

Cite this